Lumida
/UNH
⌘K
UnitedHealth Group Inc

UnitedHealth Group Inc

UNH
$379.09USD-2.37%-9.19 today

MARKET CAP

340.3B

P/E (TTM)

20.8x

FWD P/E

18.0x

DAY RANGE

$376 – $392

52W RANGE

$256
$462

AI Summary

Stalk
TrimMedium

UNH has broken below critical horizontal support and entered a Stage 4 decline, trading under its major EMAs and SMAs. The medium-term bias remains bearish, and despite extreme oversold conditions, there is no clear signal of a sustained reversal. Execution should be deferred, trimming into any rally toward the declining 9/20 EMAs and 50 SMA in the 391–396 resistance area.

  • Adjusted EPS jumped 56% YoY to $6.38 in Q2
  • Q2 revenue reached $112 B, topping expectations and showcasing scale
  • Commercial segment faces >11% medical cost trend, squeezing margins
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$285.3B$324.2B$371.6B$400.3B$447.6B
YoY %+10.9%+13.6%+14.6%+7.7%+11.8%
P / Sales1.7x1.5x1.4x1.2x0.7x
EV / Sales2.1x1.9x1.8x1.6x1.1x
Gross Profit, Adj.$98.4B$113.3B$129.7B$136.1B$133.6B
YoY %+0.6%+15.2%+14.5%+4.9%-1.9%
Margin %34.5%35.0%34.9%34.0%29.8%
EV / Gross Profit6.0x5.5x5.1x4.7x3.6x
EBITDA, Adj.$24.7B$31.8B$36.3B$36.4B$23.3B
YoY %-2.2%+28.6%+14.1%+0.2%-35.9%
Margin %8.7%9.8%9.8%9.1%5.2%
EV / EBITDA24.0x19.7x18.0x17.6x20.8x
EBIT$21.6B$28.4B$32.4B$32.3B$19.0B
YoY %-3.4%+31.4%+13.8%-0.2%-41.3%
Margin %7.6%8.8%8.7%8.1%4.2%
EV / EBIT27.5x22.1x20.3x19.8x25.5x
Net Income$17.3B$20.1B$22.4B$14.4B$12.1B
YoY %+12.2%+16.4%+11.2%-35.6%-16.3%
Net Margin6.1%6.2%6.0%3.6%2.7%
EPS (GAAP)$18.08$21.18$23.86$15.51$13.23
YoY %+12.8%+17.1%+12.7%-35.0%-14.7%